Business Wire

CQN-THE-GENEVA-ASSOC.

6.3.2017 16:45:15 CET | Business Wire | Press release

Share
CORRECTING and REPLACING: The Geneva Association: How Will Risk Modelling Shape the Future of Risk Transfer? Global Experts Lead the Way

First paragraph, second sentence of release, the date should be 9th March 2017 instead of 8th March 2017.

The corrected release reads:

THE GENEVA ASSOCIATION: HOW WILL RISK MODELLING SHAPE THE FUTURE OF RISK TRANSFER? GLOBAL EXPERTS LEAD THE WAY

Leading think tank of the international insurance industry, The Geneva Association, welcomes top international experts to discuss and explore the issue – “How Will Risk Modelling Shape the Future of Risk Transfer?” This scientific seminar is co-organised with the SCOR Foundation and hosted at the SCOR Paris headquarters on 9th March 2017. It will inform a ground-breaking research report by The Geneva Association’s Extreme Events and Climate Risk Research Programme, publishing in June 2017.

The last three and a half decades have witnessed a general trend of rising economic losses associated with extreme events. This is due to multiple factors, including increased concentration of people and assets in exposed areas such as coastal regions, poor development planning and related practices, highly sophisticated but vulnerable global production processes and the increasing severity and frequency of extreme weather-related events linked to a changing climate.

Risk analysis is the foundation for informed decision-making, increasing the understanding of the characteristics of risk, supporting risk pricing, and evaluating cost–benefits of various risk management strategies. In the mid-1980s and early 1990s, a number of major catastrophes in North America and Europe led to unprecedented high losses, resulting in insolvencies and/or bankruptcies in the insurance sector, and pointing to the need for a more rigorous and quantifiable approach to assessing and underwriting risks.

The development and utilization of catastrophe risk models (cat models) over the last 25 years has revolutionized the (re)insurance industry’s approach to pricing, underwriting and managing their complex risk portfolios. Beyond the insurance sector, the international development community has also adopted these models to help governments better understand risk and make risk-based decisions, helping improve disaster and climate risk management decisions.

The seminar brings together leading international experts from the (re)insurance industry, risk modelling community, international organizations, international donors, governments and the scientific community to share experiences and explore opportunities for strengthened cooperation and partnerships. The programme will examine the following critical issues:

(i) Enhancing current cat models – building on lessons learned from their development and utilization over the last 25 years;

(ii) Finding effective pathways to expand risk information and cat risk modelling tools to support public-sector decisions; and,

(iii) Harnessing the latest scientific and technological developments for a new generation of forward-looking risk models.

Dr. Maryam Golnaraghi, Director of the Extreme Events and Climate Risks Research Programme at The Geneva Association, said: “As one of its top priorities, The Geneva Association is convening a diverse group of leading experts in the industry, cat modelling, and various areas of science and technology to explore how risk modelling can shape the future of risk transfer around the world. Specifically, we are not only exploring opportunities to enhance current cat modelling approaches, but also opportunities for harnessing scientific and technological advancements in areas such as environmental surveillance, climate monitoring and forecasting, engineering, big data, and artificial intelligence for development of the new generation of systems-based risk models that can innovate risk transfer.”

Anna Maria D’Hulster, Secretary General of the Geneva Association said, “The insurance industry has deep risk knowledge and is working at the forefront of risk assessment, risk pricing and risk transfer. Public-private partnerships could be instrumental in helping the public sector in developing risk-informed preventive measures and risk transfer programmes that help government, businesses and individuals with managing their risks.”

ENDS

Notes to Editors

The Geneva Association is the leading international insurance think tank for strategically important insurance and risk management issues. It is a unique platform for dialogue between leaders of the insurance industry and key decision-makers at the international and national levels to evidence the important social and economic role of the insurance industry.

The Geneva Association identifies fundamental trends and strategic issues where insurance plays a substantial role or which influence the insurance sector. Through the development of research programmes, regular publications and the organisation of international meetings, The Geneva Association serves as a catalyst for progress in the understanding of risk and insurance matters and acts as an information creator and disseminator.

The Geneva Association membership comprises a statutory maximum of 90 chief executive officers (CEOs) from the world’s top insurance and reinsurance companies. It organises international expert networks and manages discussion platforms for senior insurance executives and specialists as well as policy-makers, regulators and multilateral organisations.

Established in 1973, The Geneva Association, officially the “International Association for the Study of Insurance Economics”, is based in Zurich, Switzerland and is a non-profit organisation funded by its membership.

www.genevaassociation.org

Contact:

The Geneva Association
Isabel Barratt
Communications Manager
+41 44 200 49 96
isabel_barratt@genevaassociation.org

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye